Meet Jeff
Jeff is a co-founder of Monocacy Therapeutics, an oncology-focused biotechnology company, where he serves in an advisory capacity.
Jeff was Co-Founder and CEO of Sonoma Biotherapeutics from 2019 to 2025, where he led the development of engineered regulatory T cell therapies for autoimmune diseases. From 2015 to 2019, he served as President and CEO of the Parker Institute for Cancer Immunotherapy, advancing next-generation cancer immunotherapies through coordinated research and clinical programs.
Jeff has served on the board of Gilead Sciences since 2020. Earlier in his career, he was the founding Director of the NIH-funded Immune Tolerance Network, overseeing a global clinical research platform focused on transplantation, autoimmunity, allergy and asthma. He also served as Director of the UCSF Diabetes Center and held senior academic and leadership positions at the University of California, San Francisco.
Jeff is the A.W. and Mary Margaret Clausen Distinguished Professor Emeritus at UCSF and has published more than 500 scientific papers. His work contributed to the development of abatacept, ipilimumab and teplizumab, the first FDA-approved therapy to delay the onset of type 1 diabetes. He is an elected member of the National Academy of Sciences, the National Academy of Medicine and the American Academy of Arts and Sciences.
